159 related articles for article (PubMed ID: 34619755)
21. Standardized next-generation sequencing of immunoglobulin and T-cell receptor gene recombinations for MRD marker identification in acute lymphoblastic leukaemia; a EuroClonality-NGS validation study.
Brüggemann M; Kotrová M; Knecht H; Bartram J; Boudjogrha M; Bystry V; Fazio G; Froňková E; Giraud M; Grioni A; Hancock J; Herrmann D; Jiménez C; Krejci A; Moppett J; Reigl T; Salson M; Scheijen B; Schwarz M; Songia S; Svaton M; van Dongen JJM; Villarese P; Wakeman S; Wright G; Cazzaniga G; Davi F; García-Sanz R; Gonzalez D; Groenen PJTA; Hummel M; Macintyre EA; Stamatopoulos K; Pott C; Trka J; Darzentas N; Langerak AW;
Leukemia; 2019 Sep; 33(9):2241-2253. PubMed ID: 31243313
[TBL] [Abstract][Full Text] [Related]
22. Monitoring minimal residual disease in the bone marrow using next generation sequencing.
Rustad EH; Boyle EM
Best Pract Res Clin Haematol; 2020 Mar; 33(1):101149. PubMed ID: 32139014
[TBL] [Abstract][Full Text] [Related]
23. MRD Assessment in Multiple Myeloma: Progress and Challenges.
Bertamini L; D'Agostino M; Gay F
Curr Hematol Malig Rep; 2021 Apr; 16(2):162-171. PubMed ID: 33950462
[TBL] [Abstract][Full Text] [Related]
24. Single-Step IGHV Next-Generation Sequencing Detects Clonality and Somatic Hypermutation in Lymphoid Malignancies: A Phase III Diagnostic Accuracy Study.
Gazzola A; Navari M; Mannu C; Donelli R; Etebari M; Piccaluga PP
Cancers (Basel); 2023 Sep; 15(18):. PubMed ID: 37760593
[TBL] [Abstract][Full Text] [Related]
25. Defining the undetectable: The current landscape of minimal residual disease assessment in multiple myeloma and goals for future clarity.
Diamond BT; Rustad E; Maclachlan K; Thoren K; Ho C; Roshal M; Ulaner GA; Landgren CO
Blood Rev; 2021 Mar; 46():100732. PubMed ID: 32771227
[TBL] [Abstract][Full Text] [Related]
26. Prognostic value of sequencing-based minimal residual disease detection in patients with multiple myeloma who underwent autologous stem-cell transplantation.
Takamatsu H; Takezako N; Zheng J; Moorhead M; Carlton VEH; Kong KA; Murata R; Ito S; Miyamoto T; Yokoyama K; Matsue K; Sato T; Kurokawa T; Yagi H; Terasaki Y; Ohata K; Matsumoto M; Yoshida T; Faham M; Nakao S
Ann Oncol; 2017 Oct; 28(10):2503-2510. PubMed ID: 28945825
[TBL] [Abstract][Full Text] [Related]
27. Comprehensive characterization of circulating and bone marrow-derived multiple myeloma cells at minimal residual disease.
Waldschmidt JM; Anand P; Knoechel B; Lohr JG
Semin Hematol; 2018 Jan; 55(1):33-37. PubMed ID: 29759150
[TBL] [Abstract][Full Text] [Related]
28. Assessment of Clonotypic Rearrangements and Minimal Residual Disease in Lymphoid Malignancies.
Hussaini MO; Srivastava J; Lee LW; Nishihori T; Shah BD; Alsina M; Pinilla-Ibarz J; Shain KH
Arch Pathol Lab Med; 2022 Apr; 146(4):485-493. PubMed ID: 34343238
[TBL] [Abstract][Full Text] [Related]
29. Minimal Residual Disease in Multiple Myeloma: an Important Tool in Clinical Trials.
Gozzetti A; Bocchia M
Rev Recent Clin Trials; 2022; 17(1):9-10. PubMed ID: 34814822
[TBL] [Abstract][Full Text] [Related]
30. Next-generation sequencing-defined minimal residual disease before stem cell transplantation predicts acute myeloid leukemia relapse.
Press RD; Eickelberg G; Froman A; Yang F; Stentz A; Flatley EM; Fan G; Lim JY; Meyers G; Maziarz RT; Cook RJ
Am J Hematol; 2019 Aug; 94(8):902-912. PubMed ID: 31124175
[TBL] [Abstract][Full Text] [Related]
31. Monitoring Minimal Residual Disease in Patients with Multiple Myeloma by Targeted Tracking Serum M-Protein Using Mass Spectrometry (EasyM).
Fan H; Wang B; Shi L; Pan N; Yan W; Xu J; Gong L; Li L; Liu Y; Du C; Cui J; Zhu G; Deng S; Sui W; Xu Y; Yi S; Hao M; Zou D; Chen X; Qiu L; An G
Clin Cancer Res; 2024 Mar; 30(6):1131-1142. PubMed ID: 38170583
[TBL] [Abstract][Full Text] [Related]
32. Clonotypic Features of Rearranged Immunoglobulin Genes Yield Personalized Biomarkers for Minimal Residual Disease Monitoring in Multiple Myeloma.
Langerhorst P; Brinkman AB; VanDuijn MM; Wessels HJCT; Groenen PJTA; Joosten I; van Gool AJ; Gloerich J; Scheijen B; Jacobs JFM
Clin Chem; 2021 Jun; 67(6):867-875. PubMed ID: 33709101
[TBL] [Abstract][Full Text] [Related]
33. Molecular detection of minimal residual disease in multiple myeloma.
Bai Y; Orfao A; Chim CS
Br J Haematol; 2018 Apr; 181(1):11-26. PubMed ID: 29265356
[TBL] [Abstract][Full Text] [Related]
34. Detection of Immunoglobulin Heavy Chain Gene Clonality by Next-Generation Sequencing for Minimal Residual Disease Monitoring in B-Lymphoblastic Leukemia.
Shin S; Hwang IS; Kim J; Lee KA; Lee ST; Choi JR
Ann Lab Med; 2017 Jul; 37(4):331-335. PubMed ID: 28445014
[TBL] [Abstract][Full Text] [Related]
35. Baseline VDJ clonotype detection using a targeted sequencing NGS assay: allowing for subsequent MRD assessment.
Hultcrantz M; Rustad EH; Yellapantula V; Arcila M; Ho C; Syed MH; Papaemmanuil E; Zhang Y; Maura F; Landgren O
Blood Cancer J; 2020 Jul; 10(7):76. PubMed ID: 32699232
[No Abstract] [Full Text] [Related]
36. Is Next-Generation Sequencing the way to go for Residual Disease Monitoring in Acute Lymphoblastic Leukemia?
Kotrova M; Trka J; Kneba M; Brüggemann M
Mol Diagn Ther; 2017 Oct; 21(5):481-492. PubMed ID: 28452038
[TBL] [Abstract][Full Text] [Related]
37. Minimal residual disease detection in multiple myeloma: comparison between BML single-tube 10-color multiparameter flow cytometry and EuroFlow multiparameter flow cytometry.
Sato K; Okazuka K; Ishida T; Sakamoto J; Kaneko S; Nashimoto J; Uto Y; Ogura M; Yoshiki Y; Abe Y; Maeda A; Hamazaki H; Tsukada N; Hiragohri Y; Suzuki K
Ann Hematol; 2021 Dec; 100(12):2989-2995. PubMed ID: 34430990
[TBL] [Abstract][Full Text] [Related]
38. Eight-color multiparameter flow cytometry (EuroFlow-NGF) is as sensitive as next-generation sequencing in detecting minimal/measurable residual disease in autografts of patients with multiple myeloma.
Urushihara R; Takezako N; Yoroidaka T; Yamashita T; Murata R; Satou K; Nakao S; Takamatsu H
EJHaem; 2023 Feb; 4(1):184-191. PubMed ID: 36819171
[TBL] [Abstract][Full Text] [Related]
39. Minimal residual disease analysis in myeloma - when, why and where.
Yanamandra U; Kumar SK
Leuk Lymphoma; 2018 Aug; 59(8):1772-1784. PubMed ID: 29019452
[TBL] [Abstract][Full Text] [Related]
40. Minimal residual disease in multiple myeloma: defining the role of next generation sequencing and flow cytometry in routine diagnostic use.
Maclachlan KH; Came N; Diamond B; Roshal M; Ho C; Thoren K; Mayerhoefer ME; Landgren O; Harrison S
Pathology; 2021 Apr; 53(3):385-399. PubMed ID: 33674146
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
